The present invention relates to a novel bis-amide derivative compound or a pharmaceutically acceptable salt thereof; a method of preparation thereof; and a pharmaceutical composition for preventing or treating diseases caused by hepatitis C virus infection and health functional food for preventing or ameliorating diseases caused by hepatitis C virus infection, containing the bis-amide derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient.
The novel bis-amide derivative compound of the present invention, particularly WJCPA-126, specifically binds to the catalytic site of CypA to effectively inhibit the activity of an isomerase, and the duration of the inhibitory effect can be increased because WJCPA-126 binds to CypA with high binding affinity exhibiting a low dissociation rate (Koff). Accordingly, WJCPA-126 has nontoxic and non-immunosuppressive characteristics and can effectively inhibit HCV replication in vitro and in vivo model systems. Additionally, WJCPA-126 reactivates the host interferon response through an increase in the expression of IFN-stimulated genes (ISGs) and the inhibition of interleukin-8 (IL-8) secretion. Therefore, a series of the bis-amide derivatives including WJCPA-126 can be useful as a novel type CypA inhibitor exhibiting antiviral effect.
本发明涉及一种新型双酰胺衍
生物化合物或其药学上可接受的盐;其制备方法;以及一种预防或治疗丙型肝炎病毒感染所致疾病的药物组合物和预防或改善丙型肝炎病毒感染所致疾病的保健功能食品,其活性成分中含有该双酰胺衍
生物化合物或其药学上可接受的盐。
本发明的新型双酰胺衍
生物化合物,特别是 WJCPA-126,能与 CypA 的催化位点特异性结合,有效抑制异构酶的活性,而且由于 WJCPA-126 与 CypA 的结合亲和力高,解离率(Koff)低,因此能延长抑制作用的持续时间。因此,WJCPA-126 具有无毒、无免疫抑制的特点,可在体外和体内模型系统中有效抑制 HCV 复制。此外,WJCPA-126 还能通过增加 IFN 刺激
基因(ISGs)的表达和抑制白细胞介素-8(IL-8)的分泌来重新激活宿主的干扰素反应。因此,包括 WJCPA-126 在内的一系列双酰胺衍
生物可作为一种新型 CypA
抑制剂发挥抗病毒作用。